Article Details
Retrieved on: 2021-03-24 17:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Recorlev (levoketoconazole), Strongbridge Biopharma's oral candidate to treat endogenous Cushing's syndrome, was superior to a placebo at ...
Article found on: cushingsdiseasenews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here